As filed with the Securities and Exchange Commission on December 21, 2017        

Registration No. 333-_______
 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

                                                                                     

 

FORM F-6

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933 FOR DEPOSITARY SHARES EVIDENCED BY

AMERICAN DEPOSITARY RECEIPTS

                            

 

ASTELLAS PHARMA INC.

(Exact name of issuer of deposited securities as specified in its charter)

                            

                          

N/A

(Translation of issuer's name in English)

                          

Japan

(Jurisdiction of incorporation or organization of issuer)

                            

 

CITIBANK, N.A.

(Exact name of depositary as specified in its charter)

                            

 

388 Greenwich Street

New York, New York 10013

(212) 723-5435

(Address, including zip code, and telephone number, including area code, of depositary's principal executive offices)

                                             

 

CITIBANK, N.A. – DEPOSITARY RECEIPTS DEPARTMENT

388 Greenwich Street

New York, New York 10013

(877) 248-4237

(Name, address, including zip code, and telephone number, including area code of agent for service)

                                             

 

Copies to:

Herman H. Raspé, Esq.
Patterson Belknap Webb & Tyler LLP

1133 Avenue of the Americas

New York, New York 10036

                                             

 

It is proposed that this filing become effective under Rule 466:

 ☒

immediately upon filing.

   ☐

on (Date) at (Time).

 

If a separate registration statement has been filed to register the deposited shares, check the following box:  ☐

 

CALCULATION OF REGISTRATION FEE

Title of Each Class of

Securities to be Registered

Amount to be

Registered

Proposed Maximum

Offering Price

Per Unit* 

Proposed Maximum

Aggregate

Offering Price**  

Amount of

Registration Fee 

American Depositary Shares (“ ADSs ”), each ADS representing the right to receive one (1) share of common stock of Astellas Pharma Inc.

50,000,000

ADSs

$5.00 $2,500,000.00 $311.25

  *

Each unit represents 100 ADSs.

 

**

Estimated solely for the purpose of calculating the registration fee. Pursuant to Rule 457(k), such estimate is computed on the basis of the maximum aggregate fees or charges to be imposed in connection with the issuance of American Depositary Shares.

 

I- 1

 

 

PART I

 

INFORMATION REQUIRED IN PROSPECTUS

 

Cross Reference Sheet

 

Item 1. DESCRIPTION OF SECURITIES TO BE REGISTERED

  

 

 

Item Number and Caption

 

Location in Form of American

Depositary Receipt (“ Receipt ”)

Filed Herewith as Prospectus  

     
1. Name of Depositary and address of its principal executive office   Face of Receipt - Introductory Article
       
2. Title of Receipts and identity of deposited securities   Face of Receipt - Top center.
       
 

Terms of Deposit:

       
  (i) The amount of deposited securities represented by one American Depositary Share (“ ADS ”)   Face of Receipt - Upper right corner.
         
  (ii) The procedure for voting, if any, the deposited securities   Reverse of Receipt - Paragraphs 12, 14 and 17
         
  (iii) The procedure for collecting and distributing dividends  

Face of Receipt - Paragraphs 4 and 8;

Reverse of Receipt - Paragraphs 13, 14 and 17

         
  (iv) The procedure for transmitting notices, reports and proxy soliciting material  

Reverse of Receipt - Paragraphs 11 and 12

  

         
  (v) The sale or exercise of rights   Reverse of Receipt - Paragraphs 13 and 14
         
  (vi) The deposit or sale of securities resulting from dividends, splits or plans of reorganization  

Face of Receipt - Paragraphs 4 and 8;

Reverse of Receipt – Paragraphs 13, 14, 16 and 17 

         
  (vii) Amendment, extension or termination of the deposit arrangements   Reverse of Receipt – Paragraphs 18 and 19 (no provision for extension)
         
  (viii) The rights that holders of Receipts have to inspect the transfer books of the Depositary and the list of Receipt holders   Face of Receipt - Paragraph 3

 

I- 2

 

 

         
  (ix) Any restrictions on the right to transfer or withdraw the underlying securities   Face of Receipt - Paragraphs 2, 4, 5, and 6
         
  (x) Any limitation on the Depositary’s liability  

Face of Receipt - Paragraphs 1 and 8;

Reverse of Receipt - Paragraphs 12, 15 and 17

         
3. Fees and charges that a holder of Receipts may have to pay, either directly or indirectly   Reverse of Receipt – Paragraph 20
         
Item 2. AVAILABLE INFORMATION   Reverse of Receipt - Paragraph 11

 

Based on the reasonable good faith belief of the Depositary after exercising reasonable diligence, the registrant represents that, as of the date hereof, Astellas Pharma Inc. (the “ Company ”) publishes in English the information contemplated in Rule 12g3-2(b) under the United States Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), on its internet website or through an electronic information delivery system generally available to the public in the Company's primary trading market. As of the date hereof the Company's internet website is www.astellas.com. The information so published by the Company cannot be retrieved from the Commission's internet website, and cannot be inspected or copied at the public reference facilities maintained by the Commission.

  

I- 3

 

 

prospectus

 

IN ACCORDANCE WITH GENERAL INSTRUCTIONS III. B OF FORM F-6, THIS PAGE AND THE FORM OF AMERICAN DEPOSITARY RECEIPT ATTACHED AS AN EXHIBIT TO THIS F-6 REGISTRATION STATEMENT CONSTITUTE THE PROSPECTUS RELATING TO THE AMERICAN DEPOSITARY SHARES TO BE ISSUED PURSUANT TO THIS F-6 REGISTRATION STATEMENT.

 

I- 4

 

 

PART II

 

INFORMATION NOT REQUIRED IN PROSPECTUS

 

Item 3. EXHIBITS

 

(a) The agreement between Citibank, N.A., as depositary (the “ Depositary ”), and all holders and beneficial owners from time to time of American Depositary Shares registered hereunder. – Filed herewith.

 

(b) Any other agreement to which the Depositary is a party relating to the issuance of the American Depositary Shares registered hereunder or the custody of the deposited securities. — None.

 

(c) Every material contract relating to the deposited securities between the Depositary and the issuer of the deposited securities in effect at any time within the last three years. — None.

 

(d) Opinion of Patterson Belknap Webb & Tyler LLP, counsel for the Depositary, as to the legality of the securities to be registered. – Filed herewith.

 

(e) Certification under Rule 466. – Filed herewith.

 


Item 4. UNDERTAKINGS

 

(a) The Depositary hereby undertakes to make available at the principal office of the Depositary in the United States, for inspection by holders of the Receipts, any reports and communications received from the issuer of the deposited securities which are both (1) received by the Depositary as the holder of the deposited securities, and (2) made generally available to the holders of the underlying securities by the issuer.

 

(b) The Depositary undertakes to prepare a separate document stating the amount of any fee charged and describing the service for which it is charged and to deliver promptly a copy of such fee schedule without charge to anyone upon request. The Depositary undertakes to notify each registered holder of a Receipt thirty days before any change in the fee schedule.

 

II- 1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that all the requirements for filing on Form F-6 are met and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on the 21st day of December, 2017.

 

 

Legal entity created by the agreement set forth in the American Depositary Receipts evidencing American Depositary Shares representing the right to receive shares of common stock of Astellas Pharma Inc.

     
  CITIBANK, N.A., as Depositary
     
  By: /s/ Mark Gherzo
    Name:  Mark Gherzo
    Title:

Vice President and

Attorney-in-Fact

  

II- 2

 

 

Index of Exhibits

 

Exhibit Document

Sequentially

Numbered Page

     
(a)

Form of ADR 

 
     
(d)

Opinion of Counsel to the Depositary

 
     
(e) Rule 466 Undertaking  

Astellas Pharma (PK) (USOTC:ALPMY)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Astellas Pharma (PK) Charts.
Astellas Pharma (PK) (USOTC:ALPMY)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Astellas Pharma (PK) Charts.